Enhanced expression of CTLA-4 (CD152) on CD4+ T cells in HIV infection

Clinical and Experimental Immunology

Volumn 115, Issue 3, 1999, Pages 451-457

  Steiner, K ^c   Waase, I ^a   Rau, T ^b   Dietrich, M ^a   Fleischer, B ^c   Broker B M ^a  

^a BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^b Centre for Cardiology   (Germany)

^c Bernhard Nocht Institut ^*

Author keywords

CTLA 4; HIV

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PHYTOHEMAGGLUTININ;

ADULT; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; LIGAND BINDING; LYMPHOCYTE ACTIVATION; MALE; MONONUCLEAR CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

ADULT; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOCONJUGATES; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MITOGENS; PHYTOHEMAGGLUTININS;

EID: 0033033518     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00806.x     Document Type: Article

References (45)

1. Freeman GJ, Lombard DB, Gimmi CD et al. CTLA-4 and CD28 mRNAs are coexpressed in most activated T cells after activation: expression of CTLA-4 and CD28 messenger RNA does not correlate with the pattern of lymphokine production. J Immunol 1992; 149:3795-801.
2. Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, Damle NK. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 1992; 176:1595-604.
3. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994: 1:405-13.
4. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182:459-65.
5. Linsley PS. Distinct roles for CD28 and cytotoxic T lymphocyte associated molecule-4 during T-cell activation? J Exp Med 1995; 182:289-92.
6. Allison JP, Krummel MF. The yin and yang of T-cell costimulation. Science 1995; 270:932-3.
7. Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995; 270:985-8.
8. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone J, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3:541-7.
9. Kearney ER, Walunas TL, Karr RW, Morton PA, Loh DY, Bluestone JA, Jenkins MK. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent of CD28 costimulation and inhibited by CTLA-4. J Immunol 1995; 155:1032-6.
10. McCoy K, Camberis M, Le Gros G. Protective immunity to nematode infection is induced by CTLA-4 blockade. J Exp Med 1997; 186:183-7.
11. Perrin PJ, Maldonado JH, Davis TA, June CH, Racke MK. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J Immunol 1996; 157:1333-6.
12. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271:1734-6.
13. Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, Burg MB, Allison JP. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 1997; 94:8099-103.
14. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997; 7:445-50.
15. Bluestone JA. Is CTLA-4 a master switch for peripheral T cell tolerance? J Immunol 1997; 158:1989-93.
16. Vyth-Dreese FA, Dellemijn TAM, Majoor D, de Jong D. Localization in situ of the co-stimulatory molecules B7.1, B7.2, CD40 and their ligands in normal human lymphoid tissue. Eur J Immunol 1995; 25:3023-9.
17. Castan J, Tenner-Racz K, Racz P, Fleischer B, Bröker BM. Accumulation of CTLA-4 expressing T lymphocytes in the germinal centres of human lymphoid tissues. Immunol 1997; 90:265-71.
18. Caslan J, Fleischer B, Bröker BM. Transient expression of CTLA-4 on medullary thymocytes. Med Microbiol Immunol 1998; 187:49-52.
19. Verwilghen J, Lovis R, De Broer M, Linsley P, Haines GK, Koch AE, Pope RM. Expression of functional B7 and CTLA-4 on rheumatoid synovial T cells. J Immunol 1994; 153:1378-85.
20. Nisticò L, Buzzetti R, Pritchard LE et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type I diabetes. Hum Molec Genetics 1996; 5:1075-80.
21. Marron MP, Raffel LJ, Garchon H-J et al. Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Hum Molec Genetics 1997; 6:1275-82.
22. Van der Auwera BJ, Vandewalle CL, Shuit FC, De Winnock F, Leeuw IH, Van Imschoot S, Lamberigts G, Gorus FK. CTLA4 gene polymorphism confers susceptibility to insulin-dependent diabetes mellitus (IDDM) independently from age and from other genetic or immune disease markers. The Belgian Diabetes Registry. Clin Exp Immunol 1997; 110:98-103.
23. Yanagawa T, Taniyama M, Enomoto S, Gomi K, Maruyama H, Ban Y, Saruta T. CTLA4 gene polymorphism confers susceptibility to Grave's disease in Japanese. Thyroid 1997; 7:843-6.
24. Donner H, Braun J, Seidl C et al. Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto's thyroiditis and Addison's disease. J Clin Endocrinol Metab 1997; 82:4130-2.
25. Mahalingam M, Peakman M, Davies ET et al. T cell activation and disease severity in HIV infection. Clin Exp Immunol 1993; 93:337-43.
26. Ho H-N, Hultin LE, Mitsuyasu RT et al. Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens. J Immunol 1993; 150:3070-9.
27. Mahalingam M, Pozniak A, Mcmanus TJ, Vergani D, Peakman M. Cell cycling in HIV-infection: analysis of in vivo, activated lymphocytes. Clin Exp Immunol 1995; 102:481-6.
28. γδ T cells but impaired interleukin-2-induced upregulation in HIV-1 infection. AIDS 1997; 11:838-9.
29. Benito JM, Zabay JM, Gil J et al. Quantitative alterations of the functionally distinct subsets of CD4 and CD8 T lymphocytes in asymptomatic HIV infection: changes in the expression of CD45RO, CD45RA, CD11b, HLA-DR and CD25 antigens. J Acquir Immun Def Syndr Hum Retrovir 1997; 14:128-35.
30. Bentwich Z, Kalinkovich A, Weisman Z, Grossman Z. Immune activation in the context of HIV infection. Clin Exp Immunol 1998; 111:1-2.
31. Trumpfheller C, Tenner-Racz K, Racz P, Fleischer B, Frosch S. Expression of macrophage inflammatory protein MIP-1α, MIP-1β, and RANTES genes in lymph nodes from HIV+ individuals: correlation with a Thl type cytokine respond. Clin Exp Immunol 1998; 112:92-99.
32. CDC 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41:1-17.
33. Wang H, Shih CC-Y, Waters JB, Balderas RS, Rosenberg J, Huang EC-M, Chen Z. CD152 (CTLA-4) Workshop: expression and function of CD152 on human T cells: a study using a mouse anti-human CD152 monoclonal antibody BNI3.1. New York: Garland Publishing Inc., 1997:97-98.
34. Emery S, Lane CL. Immune reconstitution in HIV infection. Curr Opin Immunol 1997; 9:568-72.
35. Roederer M. Getting to the HAART of T cell dynamics. Nat Med 1998; 4:145-6.
36. Vingerhoets JH, Vanham GL, Kestens LL et al. Increased cytolytic T lymphocyte activity and decreased B7 responsiveness are associated with CD28 down-regulation on CD8+ T cells from HIV-infected subjects. Clin Exp Immunol 1995; 100:425-33.
37. Moosig F, Csernok E, Wang G, Gross WL. Costimulatory molecules in Wegener's granulomatosis (W.G.): lack of expression of CD28 and preferential upregulation of its ligands B7/1 (CD80) and B7/2 (CD86). Clin Exp Immunol 1998; 114:113-8.
38. Miedema F, Petit AJ, Terpstra FG et al. Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ helper T cell depletion occurs. J Clin Invest 1988; 82:1908-14.
39. Clerici M, Stocks NI, Zajac RA, Boswell NR, Lucey DR, Via CS, Shearer GM. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J Clin Invest 1989; 84:1892-9.
40. Graters RA, Terpstra FG, De Jong R, Van Noesel CJM, Van Lier RAW, Miedema F. Selective loss of T cell functions in different stages of HIV infection. Eur J Immunol 1990; 20:1039-44.
41. Vingerhoets J, Dohlsten M, Penne G, Colebunders R, Sansom D, Bosmans E, Kestens L, Vanham G. Superantigen activation of CD4+ and CD8+ T cells from HIV-infected subjects: role of costimulatory molecules and antigen-presenting cells (APC). Clin Exp Immunol 1998; 111:12-19.
42. Ameisen JC, Capron A. Cell dysfunction and depletion in AIDS: the programmed cell death hypothesis. Immunol Today 1991; 12:102-5.
43. Meyaard L, Otto SA, Jonker RR, Mijnster MJ, Keel RP, Miedema F. Programmed death of T cells in HIV-1 infection. Science 1992; 257:217-9.
44. Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen JC. Activation-induced-cell death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992; 175:331-40.
45. Meyaard L, Otto SA, Keet IP, Roos MT, Miedema F. Programmed death of T cells in human immunodeficiency virus infection. No correlation with progression to disease. J Clin Invest 1994; 93:982-8.